- Details
- (Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...
|
- Details
- (Length of Discussion: 4 min) Tamara Bavendam talks with Diane Newman about preventing women’s urology issues and she shares details about her research consortium she initiated with the goal of developing the evidence base for the field of bladder with hopes to eventually have the evidence to tell physicians and clinicians how to prevent bladder problems in women. Biographies: Tamara Bavendam MD,...
|
- Details
- (Length of interview: 12 minutes) Sandy Engberg shares a study with Diane Newman that she recently presented. An NIH funded, double-blinded study, evaluating acupuncture for urinary incontinence in women. They successfully recruited women 25 years of age or older who had been incontinent for at least three months, had at least two accidents per day or per week from a baseline bladder diary. Biogra...
|
- Details
- (Length of Discussion: 20 min) Herb Lepor presents the current optimal management of localized prostate cancer including an in-depth review of focal ablation. He highlights technique, criteria for appropriate patient selection, and the value of counseling to managing expectations. Biography: Herbert Lepor, MD, Professor, Department of Urology, Professor, Department of Biochemistry and Molecular Ph...
|
- Details
- (Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...
|
- Details
- A conversation with Lysanne Campeau and Ben Brucker on treatment options for Multiple Sclerosis patients who present with neurologic disease. In this at-risk population, clinicians must consider comorbities, polypharmacy and the level of disability for each patient. The role of counseling appropriately to include the patient in the treatment decision plan is a routine practice for these providers....
|
- Details
- (Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...
|
- Details
- Dan George and Tian Zhang share their views on monitoring treatment toxicities that patients with renal cell carcinoma may experience. Emphasis is placed on counseling patients on expectations and managing baseline comorbities. Maintaining prescribed treatment schedule while focused on quality of life remains the challenging goal for an effective treatment outcome. Biographies: Tian Zhang, MD, Ass...
|
- Details
- (Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...
|
- Details
- (Length of Discussion: 8 min) Tian Zhang discusses with Alicia Morgans the STARTAR trial, a phase 2 enrolling high risk prostate cancer patients with Gleason 7 T3 or Gleason 8-10 who have developed PSA recurrence and adding systemic agents to standard of care with the goal of extending the lives of this patient population. They discuss logistics for patients who may qualify for this trial. Biograp...
|
